AMBER WOODFIELD: Open Payments
NPI 1104828433 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$792 in 19 payments from 13 companies in 2025. Trend: 2023 $447 · 2024 $270 · 2025 $792
Food & beverage: $792
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $186 |
| GlaxoSmithKline, LLC. | 1 | $122 |
| ABIOMED | 1 | $121 |
| Novo Nordisk Inc | 1 | $113 |
| SANOFI-AVENTIS U.S. LLC | 2 | $55 |
| Lilly USA, LLC | 2 | $37 |
| SI-BONE, INC. | 1 | $28 |
| Astellas Pharma US Inc | 1 | $25 |
| Amgen Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $23 |
Products named: REXULTI, SHINGRIX, Wegovy, TZIELD, Veozah, EVENITY, Dexcom G6 Transmitter, PROCLAIM.
Industry payments across TX — which companies pay providers there.
